| Date | Time | Event | ||
|---|---|---|---|---|
| Tuesday 18th February 2025 |
8:00 am - 9:30 am | Registration and Coffee | ||
| SESSION 1 | INAUGURATION | |||
| 9:30 am – 10:00 am | Welcome Address. K. N. Ganesh (JNCASR) Inaugural Address: President (JNCASR) |
|||
| 10:00am | PL1 | Mano Manoharan (Alnylam) |
Living in the Universe of Nucleic Acid-based Medicines, An Overview | |
| 10:45am | IL 1 | Annemieke Aartsma - Rus (Leiden University) |
The importance of involving patients in therapy development: Lessons learned from Duchenne exon skipping | |
| 11:15 am | COFFEE BREAK | |||
| 11:45 am | IL 2 | Jyotirmayee Dash (IACS, Kolkata) |
Therapeutic Applications of Nucleic Acid Secondary Structures | |
| 12:15 pm | IL 3 | Dev Arya (Clemson University) |
A Comparative Study of Antisense Oligomers in Inhibiting Prokaryotic Gene Expression | |
| 12:45 pm | ST 1 | Sandeep Eswarappa | Programmable Induction of Therapeutic Stop Codon Readthrough via RNA-Targeting CRISPR-dCas13 | |
| 1:00 pm | Buffett Lunch, Exposition & Posters | |||
| SESSION 2 | CHEMICAL MODIFICATIONS: STRUCTURE AND FUNCTION | |||
| 2:00 pm | IL 4 | Thomas Carell (LMU, Munich ) |
The prebiotic origin of RNA nucleosides and translation | |
| 2:30 pm | IL 5 | Martin Egli (Vanderbilt University) |
Structure- and Computational Modeling- Guided Engineering of RNA into Therapeutic Agents | |
| 3:00 pm | IL 6 | Ashwin Dalal (CDFD) |
indian Genomics Lanscape: Achievements and Opportunities | |
| 3:30 pm – 5.00 pm | TEA BREAK AND POSTER SESSION | |||
| 5:00 pm | IL 7 | Sujata Sonti (GSK) |
Pharmaceutical Development and Engineering Considerations for Next-Gen Oligonucleotide Therapeutics | |
| 5:30 pm | IL 8 | Sritama Bose (NATA, UK) |
Thiol-specific Novel Linkers for the Synthesis of Oligonucleotide Conjugates | |
| 6:00 pm | IL 9 | Ishu Saraogi (IISER Bhopal) |
Synthetic Approaches to Modulate Nucleic Acid Structure and Function | |
| 6:30 pm | IL 10 | Daniel Blessing (Haya) |
Developing Next Generation lncRNA-Targeting Therapeutics: Key Considerations for ASO Candidate Design | |
| 7:00 pm | DINNER | |||
| Wednesday 19th February 2025 |
SESSION 3 | DELIVERY AND TARGETING | ||
| 9:00 am | IL 11 | Takeshi Wada (Tokyo University of Science) |
Development of New Synthetic Approaches for P- modified Oligonucleotides Based on P(III) Chemistry | |
| 9:30 am | IL 12 | T. P. Prakash (Ionis Pharmaceuticals) |
An Overview of the Evolution of Medicinal Chemistry at Ionis for RNA-targeted Therapeutics | |
| 10:00 am | IL 13 | Alfica Sehgal (Judo Bio) |
Extending Oligonucleotide Delivery and Gene Knockdown to Specific Cell Types in Kidney | |
| 10:30 am | IL 14 | K. G. Rajeev (Verve Therapeutics) |
GalNAc-LNPs to Deliver Gene Editing Therapeutics to Liver | |
| 11:00 AM | COFFEE BREAK | |||
| 11:30am | IL 15 | Muthusamy Jayaraman (Orna) |
In vivo Delivery of LNP- encapsulated RNA to Extra- Hepatic Tissues in NHPs | |
| 12:00 | IL 16 | Martin Maier (Alnylam) |
Interfering with Cancer: Advancing RNAi Therapeutics Towards Oncology Indications | |
| 12:30 pm | IL 17 | Ekambar Kandimalla (Prime Medicine) |
Optimization of RNA for the Delivery of Prime Editors | |
| 1:00 pm | Buffett Lunch, Exposition & Posters | |||
| SESSION 5 | CHEMICAL MODIFICATIONS: STRUCTURE AND FUNCTION | |||
| 2:00 pm | IL 18 | Chandra Vargeese (Wave) |
Improving the pharmacological properties of oligonucleotides through stereopure design | |
| 2:30 pm | IL 19 | P. I. Pradeepkumar (IIT Bombay) |
Molecular Insights into the Effects of Single DNA Modification in crRNA on Cas9 Structure and Function | |
| 3:00 pm | IL 20 | S. G. Srivatsan (IISER-Pune) |
Probing nucleic acid architecture and function using responsive nucleoside probes | |
| 3:30 pm –5:00 pm | TEA BREAK AND POSTER SESSION | |||
| SESSION 6 | SPLICE MODULATION, DMD AND DELIVERY | |||
| 5:00 pm | IL 21 | Surajit Sinha (IACS, Kolkata) |
Next Generation Phosphorodiamidate Morpholino Oligonucleotides for Broad Applications | |
| 5:30 pm | IL 22 | Pallavi Lonkar (PepGen) |
Broadening the Understanding of Peptide Conjugated Oligonucleotides Platform to Expand Therapeutic Use | |
| 6:00 pm | IL 23 | Rakesh Veedu (Murdoch University) |
Evaluation of Novel Antisense Oligonucleotide Chemistries and Designs for Enhanced Splice Switching | |
| 6:30 pm – 7:30 pm | CULTURAL PROGRAM | |||
| Thursday 20th February 2025 |
SESSION 7 | MANUFACTURING, CHEMICAL SYNTHESIS AND ANALYTICAL METHODS | ||
| 9:00 am | IL 24 | Masad Damha (McGill University) | Sustainable Methods for Oligonucleotide Synthesis & Construction of Long RNA (>100 nt) Sequences | |
| 9:30 am | IL 25 | Yogesh Sanghvi (Rasayan) |
Development of a Kilogram- Scale Manufacturing Route for Bis-Tac-dG and Guadecitabine: A Dinucleotide DNA Methyltransferase Inhibiton | |
| 10:00 am | IL 26 | Soham Mandal (Axo Labs) |
Evaluation of GalNAc assemblies for siRNA delivery and comparison of bioanalytical assays to assess pharmacokinetics and biodistribution | |
| 10:30 am | IL 27 | Denise Ramsden (KorroBio) |
Oligonucleotide Promoted Editing of RNA | |
| 11:00 AM | COFFEE BREAK | |||
| SESSION 8: | LIPIDIC NUCLEIC ACIDS AND NUCLEIC ACID SECONDARY STRUCTURES | |||
| 11:30 am | IL 28 | Ramon Eritja (IQACCSIC, Barcelona) |
DNA Nanostructures for Drug Delivery | |
| 12:00 | IL 29 | Beatriz Llamusí Troísi (Arthex) |
Fatty Acid Conjugation as a BBB Shuttle to Enable Efficient Oligonucleotide Delivery into the CNS | |
| 12:30 | IL 30 | Philippe BARTHELEMY (Univ Boreaux) |
Nucleolipid-modified G4- Oligonucleotides: from supramolecular assemblies to bioactivity in cancer cells | |
| 1:00 pm | Group photo, Buffett Lunch, Exposition & Posters | |||
| 2:00 pm | Free time – Sight seeing | |||
| Friday 21st February 2025 |
SESSION 9 | FUTURE DIRECTIONS I | ||
| 9:00 am | IL 31 | Anand Subramoni (Eli Lilly) |
Overcoming drug delivery challenge for nucleic acid modalities | |
| 9:30 am | IL 32 | Vasant Jadhav (Alnylam) |
Expanding the Scope of RNAi Therapeutics | |
| 10:00 am | IL 33 | Ichiro Hirao (Xenolis) |
High-affinity DNA Aptamers (XenoAptamers) Through Genetic Alphabet Expansion | |
| 10:30 am | IL 34 | T. Govindaraju (JNCASR) |
Molecular Therapeutics Targeting Nucleic Acids | |
| 11:00 AM | COFFEE BREAK | |||
| SESSION 10 | FUTURE DIRECTIONS II | |||
| 11:30 am | IL 35 | Poulami Talukder (Tiba Biotech) |
RNABL: A Novel RNA Delivery Modality Based on Ionizable Alkylamine-modified Polyester Scaffolds | |
| 12:00 pm | ST 2-ST 6 | 6 x Short talks (10 mins) |
TBA | |
| 1:00 pm | Buffett Lunch, Exposition & Posters | |||
| 1:50 pm | ST 7-ST 14 | 8 x Short talks (10 mins) |
TBA | |
| 3:10 pm | ST 15-ST 21 | 9 x Sponsor talks (5 mins) |
TBA | |
| 3:55 pm | TEA BREAK | |||
| SESSION 11 | FINAL KEYNOTE SESSION | |||
| 4:15 pm | IL 36 | Hiroshi Abe (Nagoya University) |
Rapid, Complete Chemical Synthesis of mRNA for Therapy | |
| 4:45 pm | PL 2 | David Corey (UT Southwestern) |
Future of Nucleic Acid Medicine | |
| 5:30 pm | VALEDICTION | |||
| 6:00 pm | Departure for Banquet and Awards function | |||
In addition to invited speakers, some abstracts/posters will be chosen for short oral presentation.
| Speaker | Title |
|---|---|
| Anand Subramony Eli Lilly, Indianapolis, USA |
Overcoming drug delivery challenge for nucleic acid modalities |
| Alfica Sehgal Judo Bio, Technology square Cambridge, MA, USA |
Extending Oligonucleotide delivery and gene knockdown to specific cell types in kidney |
| Annemieke Aartsma-Rus Leiden University Medical Center, Leiden, the Netherlands |
The importance of involving patients in therapy development Lessons learned from Duchenne exon skipping |
| Ashwin Dalal Centre for DNA Fingerprinting and Diagnostics |
Indian genomics landscape: achievements and opportunities |
| Beatriz Llamusí Troísi ARTHEx Biotech, Valencia, Spain |
Fatty acid conjugation as a BBB shuttle to enable efficient oligonucleotide delivery into the CNS |
| Chandra Vergeese Wave Life Sciences, Boston, USA |
Improving the pharmacological properties of oligonucleotides through stereopure design |
| Daniel Blessing Haya Therapeutics, Switzerland |
Developing Next Generation lncRNA-Targeting Therapeutics: Key considerations for ASO candidate design |
| David Corey UT Southwestern Medical Centre, Dallas Texas, USA |
Nuclear Localization of Argonaute is affected by Cell Density and May Relieve Repression by microRNAs |
| Dev P. Arya Department of Chemistry, Clemson University, Clemson, US |
A Comparative Study of Antisense Oligomers in Inhibiting Prokaryotic Gene Expression |
| Diane Ramsden Korrobiochem, Boston, USA |
Oligonucleotide Promoted Editing of RNA |
| Ekambar Kandimalla Prime Medicine, Cambridge, MA, 02141 |
Optimization of RNA for the Delivery of Prime Editors |
| Govindaraju. T JNCASR, Bengaluru |
Molecular theragnostic targeting nucleic acids |
| Hiroshi Abe Nagoya University, Nagoya, Japan |
Rapid, complete chemical synthesis of mRNA for therapy |
| Ichiro Hirao Xenolis Pte Ltd, Singapore |
High-affinity DNA aptamers (XenoAptamers) through genetic alphabet expansion |
| Jyotirmayee Dash IACS, Kolkata, India |
Therapeutic Applications of Nucleic Acid Secondary Structures |
| Ishu Saraogi IISER Bhopal, Bhopal, India |
Synthetic Approaches to Modulate Nucleic Acid Structure and Function |
| Martin Egli Vanderbilt University, Nashville, USA |
Structure- and Computational Modeling-Guided Engineering of RNA Oligos into Therapeutic Agents |
| Mano Manoharan Alnylam Pharmaceuticals |
Living in the world of Nucleic Acid Medicine |
| Martin Maier Alnylam Pharmaceuticals, Boston, USA |
Interfering with Cancer: Advancing RNAi Therapeutics Towards Oncology Indications |
| Masad J Damha McGill University, Montreal, Canada |
Sustainable methods for oligonucleotide synthesis & construction of long RNA (>100 nt) sequences |
| Muthuswamy Jayaraman Ornatx, Watertown, MA, USA |
In vivo Delivery of LNP-encapsulated RNA to Extra-Hepatic Tissues in NHPs |
| Philippe Barthélémy Université de Bordeaux, Bourdeaux |
Nucleolipid-modified G4-Oligonucleotides: from supramolecular assemblies to bioactivity in cancer cells |
| Pallavi Lonkar PepGen, Boston, USA |
Empowering enhanced oligo delivery platform to improve RNA modulating therapies in rare muscle diseases |
| Poulami Talukder Tiba Biotech, Boston, USA |
RNABL: A novel RNA delivery modality based on ionizable alkylamine-modified polyester scaffolds |
| P. I. Pradeepkumar IIT Bombay, Mumbai, India |
Molecular insights into the effects of single DNA modification in crRNA on Cas9 structure and function |
| Rajeev Kallanthottathil Verve Therapeutics, Boston, USA |
GalNAc-LNPs to deliver gene editing therapeutics to liver |
| Rakesh Veedu Murdoch University, Australia |
Evaluation of novel antisense oligonucleotide chemistries and designs for enhanced splice switching. |
| Ramon Eritja IQAC-CSIC, Barcelona, Spain |
DNA nanostructures for drug delivery |
| Sritama Bose Nucleic Acid Therapy Accelerator, Harwell, UK |
Thiol-specific novel linkers for the synthesis of oligonucleotide conjugates |
| S. G. Srivatsan IISER Pune, Pune, India |
Probing nucleic acid architecture and function using responsive nucleoside probes |
| Sujatha Sonti GSK, USA |
Pharmaceutical Development and Engineering Considerations for Next-Gen Oligonucleotide Therapeutics |
| Surajit Sinha IACS, Kolkata, India |
Next Generation Phosphorodiamidate Morpholino Oligonucleotides for Broad Applications |
| Takeshi Wada Department of Medicinal and Life Sciences, Tokyo University of Science, Japan |
Development of new synthetic approaches for P-modified oligonucleotides based on P(III) chemistry |
| Thazha Prakash Ionis Pharma, Carlsbad, USA |
An Overview of the Evolution of Medicinal Chemistry at Ionis for RNA-targeted Therapeutics |
| Thomas Carell LMU, Munchen, Germany |
The prebiotic origin of RNA nucleosides and translation |
| Vasant Jadhav Alnylam Therapeutics, Boston, USA |
Expanding the scope of RNAi therapeutics’ |
| Yogesh Sanghvi Rasayan, Encinitas, CA, USA |
Development of a Kilogram-Scale Manufacturing Route for Bis-Tac-dG and Guadecitabine: A Dinucleotide DNA Methyltransferase Inhibitor |